Former Attorney General Pam Bondi disclosed Wednesday that she has been diagnosed with thyroid cancer and is undergoing treatment, including surgery she had roughly two weeks ago. The 60-year-old told CBS News via text message that the diagnosis came after she left the Justice Department in April.
Bondi's departure from the DOJ and her cancer fight landed almost on top of each other. President Trump fired her on April 2 and installed Deputy Attorney General Todd Blanche as acting replacement. Somewhere in the weeks that followed, doctors found the cancer. Bondi kept it quiet and began treatment without public fanfare.
The disclosure arrived the same week Bondi is scheduled to testify Friday before the House Oversight Committee about her handling of the Jeffrey Epstein files, a subject that drew months of bipartisan criticism during her tenure. It also came alongside news that the administration has tapped her for a seat on the Presidential Council of Advisors on Science and Technology, where she will focus on artificial intelligence policy.
Vice President JD Vance issued a statement to CBS News on Wednesday morning praising Bondi's service and her continued role in the administration's orbit:
"[Bondi] has been an enormously valuable asset to the president's team, and I'm thrilled for her and for all of us that she's going to remain involved in confronting some of the most important issues the administration faces."
Katie Miller, a former White House staffer, offered a blunter assessment. Fox News reported Miller's remark: "Pam has been quietly kicking cancer's a** the last few weeks. @PamBondi has a heart of gold."
The tone from allies was consistent, gratitude for Bondi's work, confidence in her recovery, and a clear signal that the White House views her as an asset worth keeping close even after her time at DOJ ended.
Thyroid cancer, while serious, carries one of the highest survival rates among cancers. Newsmax reported that the five-year survival rate exceeds 98 percent. Bondi has undergone surgery and continues treatment, though the specific type and stage of her cancer have not been disclosed.
Bondi is not the first figure in Trump's orbit to face this diagnosis. The New York Post noted that Jared Kushner, the president's son-in-law and former adviser, also battled thyroid cancer during the first Trump administration. The disease is relatively uncommon but highly treatable when caught, a fact that should offer Bondi and her supporters genuine encouragement.
No details have emerged about where Bondi received her diagnosis or underwent surgery. The specific treatment protocol beyond the surgery itself remains private.
Bondi's time as attorney general ended abruptly. Supreme Court setbacks and broader DOJ frustrations drove the president's decision to remove her, with dissatisfaction centering on how aggressively she pursued administration priorities. The specifics of those complaints, which policies fell short, which fights went unfought, remain largely undefined in public accounts.
What is clear is that the Epstein files became a flashpoint. Congress passed a law requiring the release of those files, and Bondi's handling of the rollout drew fire from both parties. The Justice Department's internal watchdog announced last month that it will audit DOJ compliance with the release requirement.
Now Bondi faces the House Oversight Committee on Friday to answer questions about that very subject. The hearing will test whether lawmakers treat a former cabinet official battling cancer with the gravity the moment demands, or whether partisan theatrics take over.
Trump moved quickly after firing Bondi, naming Blanche to keep the department running. The transition was part of a broader pattern of personnel changes across the administration, reflecting a president willing to make hard calls when he believes an agency is underperforming.
The appointment to the Presidential Council of Advisors on Science and Technology signals that Bondi's public career is not over. The AI-focused advisory role is a different lane from law enforcement, but it keeps her inside the administration's policy apparatus at a moment when artificial intelligence regulation sits near the top of the national agenda.
That decision, bringing Bondi back into the fold weeks after letting her go from DOJ, tells its own story. Whatever frustrations led to her firing, the White House clearly believes she has more to contribute.
The broader pattern of administration officials departing under pressure has drawn media attention all year. But Bondi's case is distinct. She left, got a cancer diagnosis, underwent surgery, and is now preparing to testify before Congress and serve in a new advisory capacity, all within a matter of weeks.
Health disclosures by public officials always carry political weight, whether the person in question is a sitting president undergoing a checkup or a former cabinet member revealing a diagnosis after leaving office. Bondi chose to go public via a direct text exchange with a reporter, no press conference, no staged announcement. The approach fits someone who would rather get back to work than manage a news cycle.
Several questions linger. Why disclose now, days before high-profile congressional testimony? Was the timing driven by the hearing calendar, by the advisory appointment, or simply by the reality that the news would surface eventually? Bondi has not said.
The stage of her cancer, the full scope of her treatment plan, and her long-term prognosis remain private. Those are her decisions to make. What matters to the public is whether she can fulfill the obligations she has accepted, the Friday testimony and the advisory council seat, and on that front, the signals from her allies are uniformly confident.
Cancer does not care about politics. It does not wait for a convenient news cycle or a clean exit from government. Bondi's fight is her own, and the 98-percent survival rate should give fair-minded people on both sides of the aisle reason to wish her well, and then hold her accountable, as they would anyone else, when she sits down before the Oversight Committee on Friday.
